Louise A A Gerbens
Overview
Explore the profile of Louise A A Gerbens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
Caron A, van Huizen A, Musters A, Gerbens L, Middelkamp Hup M, Flohr C, et al.
J Eur Acad Dermatol Venereol
. 2024 Aug;
39(2):331-339.
PMID: 39087636
Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide...
2.
Li A, Musters A, Hyseni A, Gerbens L, Spuls P
Br J Dermatol
. 2024 Jul;
191(6):1012-1013.
PMID: 39005169
No abstract available.
3.
Jacobson M, Leshem Y, Apfelbacher C, Spuls P, Gerbens L, Thomas K, et al.
JAMA Dermatol
. 2024 May;
160(8):878-886.
PMID: 38776110
Importance: Outcome measurement is an essential component of value-based health care and can aid patient care, quality improvement, and clinical effectiveness evidence generation. The Harmonising Outcome Measures for Eczema Clinical...
4.
Caron A, Bloem M, El Khattabi H, de Waal A, van Huizen A, Denswil N, et al.
J Dermatolog Treat
. 2023 Dec;
35(1):2292962.
PMID: 38124505
Methotrexate is an off-label therapy for atopic dermatitis. A lack of consensus on dosing regimens poses a risk of underdosing and ineffective treatment or overdosing and increased risk of side...
5.
Thomas K, Howells L, Leshem Y, Simpson E, Apfelbacher C, Spuls P, et al.
Br J Dermatol
. 2023 Dec;
190(4):527-535.
PMID: 38123134
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed...
6.
Jacobson M, Rick J, Gerbens L, Baghoomian W, Gould L, Marzano A, et al.
Br J Dermatol
. 2023 Nov;
190(3):392-401.
PMID: 37952167
Background: Pyoderma gangrenosum (PG) is a rare ulcerative skin condition with no current standardized outcomes or outcome measures. With a rich investigational therapeutic pipeline, standardization of outcomes and improvement of...
7.
Haddadin O, Jacobson M, Chen D, Croitoru D, Dissemond J, Gontijo J, et al.
Arch Dermatol Res
. 2023 Sep;
315(10):2913-2919.
PMID: 37755505
Pyoderma gangrenosum (PG) is a rare inflammatory condition with an immense disease burden that remains understudied. With limited approved treatments and low-quality clinical evidence, PG continues to have poor patient...
8.
Leshem Y, Simpson E, Apfelbacher C, Spuls P, Thomas K, Schmitt J, et al.
Br J Dermatol
. 2023 Aug;
189(6):710-718.
PMID: 37548315
Background: Core outcome sets (COS) are consensus-driven sets of minimum outcomes that should be measured and reported in all clinical trials. COS aim to reduce heterogeneity in outcome measurement and...
9.
Lam M, Spuls P, Leshem Y, Gerbens L, Thomas K, Arents B, et al.
Br J Dermatol
. 2023 Jul;
189(4):494-496.
PMID: 37434297
No abstract available.
10.
Orfali R, Lorenzini D, Bressan A, Tanaka A, Cerqueira A, Hirayama A, et al.
An Bras Dermatol
. 2023 Jun;
98(6):814-836.
PMID: 37302894
This publication is an update of the "Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology" published in 2019, considering the novel, targeted-oriented systemic therapies for...